22nd Century VP of Regulatory Science to Present on Health Disparities Caused by Cigarette Addiction at FDLI Annual Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
22nd Century VP of Regulatory Science to Present on Health Disparities Caused by Cigarette Addiction at FDLI Annual Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Search jobs 11-May-2021 NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets
LianBio to collaborate in the development of NBTXR3, and contribute to enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy
Supports the expansion of global phase III registrational study in head and neck cancer into Greater China, with longer term strategic alignment across multiple tumor indications and therapeutic combinations
PARIS & CAMBRIDGE, Mass. & SHANGHAI & PRINCETON, N.J. (BUSINESS WIRE) $NBTX#LianBio Regulatory News:
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a partnershi
Celyad Oncology SA: Celyad Oncology to Present Data From Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
Initial clinical activity observed, with one confirmed partial response (PR) observed in this low dose (30x10
6 cells per infusion)
Regulatory News:
Celyad Oncology SA (Euronext Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T-cell (CAR T) therapies for cancer, today announced that an abstract highlighting initial clinical data from the Phase 1 IMMUNICY-1 trial of CYAD-211 has been accepted for e-poster presentation at the upcoming European Hematology Association (EHA) Virtual Congress 2021